Recurrent low- to intermediate-grade chondrosarcoma of the thumb with lung metastases: An objective response to trofosfamide

Onkologie

Volumn 30, Issue 4, 2007, Pages 201-204

  Debruyne, P R ^a,c   Dumez, H ^a,d   Demey, W ^a   Gillis, L ^d   Sciot, R ^b   Schoffski P ^a  

^a Katholieke Universiteit   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d Department of General Medical Oncology ^*  (Belgium)

Author keywords

Chondrosarcoma; Trofosfamide

Indexed keywords

DOXORUBICIN; TROFOSFAMIDE;

AGED; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURGERY; CARPAL JOINT; CASE REPORT; CHONDROSARCOMA; COMPUTER ASSISTED TOMOGRAPHY; CYSTITIS; DISEASE SEVERITY; DISTAL PHALANX; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HUMAN TISSUE; LUNG METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; SIDE EFFECT; THUMB; TRAPEZOID BONE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE NEOPLASMS; CARPOMETACARPAL JOINTS; CHEMOTHERAPY, ADJUVANT; CHONDROSARCOMA; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; THUMB; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33947600726     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000099988     Document Type: Article

References (17)

1. Dorfman HD, Czerniak B: Bone cancers. Cancer 1995;75:203-210.
2. Bovee JV, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC: Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 2005;6:599-607.
3. Somers J, Faber LP: Chondroma and chondrosarcoma. Semin Thorac Cardiovasc Surg 1999;11:270-277.
4. Reichardt P, Pink D, Tilgner J, Kretzschmar A, Thuss-Patience PC, Dorken B: Oral trofosfamide: an active and well-tolerated maintenance therapy for adult patients with advanced bone and soft tissue sarcomas. Results of a retrospective analysis. Onkologie 2002;25:541-546.
5. Latz D, Nassar N, Frank R: Trofosfamide in the palliative treatment of cancer: a review of the literature. Onkologie 2004;27:572-576.
6. Wagner A, Hempel G, Boos J: Trofosfamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the oral treatment of cancer. Anticancer Drugs 1997;8:419-431.
7. Hartmann JT, Oechsle K, Mayer F, Kanz L, Bokemeyer C: Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas. Anticancer Res 2003;23:1899-1901.
8. Blomqvist C, Wiklund T, Pajunen M, Virolainen M, Elomaa I: Oral trofosfamide: an active drug in the treatment of soft-tissue sarcoma. Cancer Chemother Pharmacol 1995;36:263-265.
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
10. Kollmannsberger C, Brugger W, Hartmann JT, Maurer F, Bohm P, Kanz L, Bokemeyer C: Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma. Anticancer Drugs 1999;10:453-456.
11. Al-Batran SE, Atmaca A, Bert F, Jager D, Frisch C, Neumann A, Orth J, Knuth A, Jager E: Dose escalation study for defining the maximum tolerated dose of continuous oral trofosfamide in pretreated patients with metastatic lung cancer. Onkologie 2004;27:534-538.
12. Brain EC, Mita A, Soulie P, Errihani H, Hardy Bessard AC, Chaouche M, Alexandre J, Delord JP, Cvitkovic E, Jasmin C, Misset JL: 6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies. J Cancer Res Clin Oncol 1997;123:227-231.
13. Vogt T, Hafner C, Bross K, Bataille F, Jauch KW, Berand A, Landthaler M, Andreesen R, Reichle A: Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer 2003;98:2251-2256.
14. La Rocca RV, Morgan KW, Paris K, Baeker TR: Recurrent chondrosarcoma of the cranial base: a durable response to ifosfamide-doxorubicin chemotherapy. J Neurooncol 1999;41:281-283.
15. McGrory JE, Rock MG, Nascimento AG, Oliveira AM: Extraskeletal myxoid chondrosarcoma. Clin Orthop Relat Res 2001;382:185-190.
16. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-1886.
17. Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-436.